MEL Medical Enterprises Ltd. of Petah Tikva at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

MEL Medical Enterprises Ltd.

P.O. Box 7166, 4917101 Petah Tikva
6 Odem st, 4951789 Petah Tikva
Telephone +972 3 9244830
Fax +972 3 9245340

This company is co-exhibitor of
Israel Export & International Cooperation Institute

Hall map

MEDICA 2019 hall map (Hall 16): stand M25

Fairground map

MEDICA 2019 fairground map: Hall 16

Our range of products

Product categories

  • 01  Electromedical Equipment / Medical Technology
  • 01.03  Surgery devices, endoscopy devices
  • 01.03.02  Instruments for the minimal-invasive surgery (MIS)

Instruments for the minimal-invasive surgery (MIS)

Our products

Product category: Instruments for the minimal-invasive surgery (MIS)



Synergo® is an advanced, minimally invasive technology for the treatment of non-muscle invasive bladder cancer (NMIBC). The treatment is based on controlled RF radiation (non-ionising microwave radiation) of the bladder tissue, along with instillations of the bladder with chemotherapy (thermochemotherapy). The patient is treated on an outpatient basis in a series of weekly one-hour treatments with no need for anaesthesia.
Synergo® System is a computer-embedded intravesical irrigation system combined with an energy-delivering unit. The System includes an RF generator that delivers radiofrequency energy at 915 MHz (the lower limit of microwave electromagnetism), a drug circulating unit, and a microprocessor with application specific software. 
The user interface consists of a computer, monitor with touch screen, and barcode reader. The software monitors and records treatment parameters in real-time during the treatment session.
The Synergo® transurethral RF ablation applicator is used for the drug intravesical instillation. The applicator is equipped with an integrated miniaturised RF antenna that radiates the bladder walls and 5 thermocouples (miniature thermometers) that monitor the bladder tissue temperature during the treatment.

The use of Synergo® was approved by the European Standard Authorities (CE) in 2001. Since then the treatment has become available in many leading medical centres. So far, thousands of patients have been treated with Synergo® worldwide and many studies (including randomised trials) have been conducted over the years. The Synergo® technology has been proven safe and efficacious in the treatment of non-muscle invasive bladder cancer in numerous routine treatment studies and clinical trials that have been published since 1995.

More Less

About us

Company details

Medical Enterprises Group is a growing and dynamic medical device company. It has its headquarters in Amsterdam, The Netherlands, where sales and marketing activities are managed. Research and Development, manufacturing, technical support and clinical activities are managed from the facility in Israel.
Our R&D staff is a multifunctional team composed of physicists, electrical and mechanical engineers, software and QA experts.
The clinical department includes trained specialists who provide medical support to urology clinics around the world, and handle clinical trials and publications.

The company is focused on developing minimally invasive therapeutic technologies which provide benefits for both patient and healthcare system.

Synergo® is available in leading medical centres worldwide. Contact info[at]synergo-medical[dot]com for your nearest urology clinic.

More Less